FOX31 Denver

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

We performed an in vivo directed evolution capsid screen in non-human primates to identify novel capsids that target the back of the eye. This involved administering a diverse library of AAV capsid ...
Seeking Alpha

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings (MGTX) plc , a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster ...
Nasdaq

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Presenter: Alex Boyne, Gene Editing Platform Manager at CellectisSession Date/Time: May 9, 2024 at 12PM ETSession Title: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular ...
Nasdaq

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and ...

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Seeking Alpha

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings (MGTX) plc , a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight ...
Forbes

Gene Technology Shows Investment Promise—Along With Ethical Concerns

Jeff Bartel is chairman and managing director of Hamptons Group, a private investment and strategic advisory firm headquartered in Miami. Gene editing technology, a major biotechnology advance, is ...
Business Insider

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and ...

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Business Wire

Couragene Co-founders Developing Gene Editing Technology for Genetic Diseases Awarded Major Federal Grant

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Couragene, a genetic medicines company using novel delivery platforms, announces today that its co-founders Yong-Hui Jiang and Jiangbing Zhou of Yale University ...